Raju Mohan Acquires 238,248 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan acquired 238,248 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $1.83 per share, for a total transaction of $435,993.84. Following the completion of the transaction, the chief executive officer now owns 1,913,276 shares in the company, valued at $3,501,295.08. The trade was a 14.22 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.

Raju Mohan also recently made the following trade(s):

• On Monday, November 25th, Raju Mohan bought 261,752 shares of Ventyx Biosciences stock. The stock was purchased at an average cost of $2.01 per share, for a total transaction of $526,121.52.

Ventyx Biosciences Price Performance

VTYX opened at $2.54 on Wednesday. Ventyx Biosciences, Inc. has a 1-year low of $1.67 and a 1-year high of $11.48. The stock has a market cap of $179.60 million, a P/E ratio of -1.08 and a beta of 0.37. The stock’s 50 day simple moving average is $2.19 and its 200 day simple moving average is $2.61.

Institutional Trading of Ventyx Biosciences

Several large investors have recently bought and sold shares of VTYX. Barclays PLC raised its stake in shares of Ventyx Biosciences by 273.1% during the 3rd quarter. Barclays PLC now owns 80,295 shares of the company’s stock worth $175,000 after buying an additional 58,776 shares during the last quarter. Geode Capital Management LLC increased its holdings in Ventyx Biosciences by 5.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,391,702 shares of the company’s stock valued at $3,034,000 after acquiring an additional 77,350 shares in the last quarter. XTX Topco Ltd acquired a new position in Ventyx Biosciences during the third quarter worth about $246,000. State Street Corp lifted its holdings in shares of Ventyx Biosciences by 0.8% in the third quarter. State Street Corp now owns 1,187,650 shares of the company’s stock valued at $2,589,000 after purchasing an additional 9,783 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Ventyx Biosciences by 19.5% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 568,479 shares of the company’s stock worth $1,239,000 after purchasing an additional 92,753 shares in the last quarter. Institutional investors and hedge funds own 97.88% of the company’s stock.

Wall Street Analyst Weigh In

VTYX has been the subject of several analyst reports. Oppenheimer reissued an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Canaccord Genuity Group reduced their price target on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price objective on shares of Ventyx Biosciences in a report on Monday, November 11th. Finally, Wells Fargo & Company reduced their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.